Polysubunit Opioid Prodrugs With Enzyme-Saturation Overdose Resistance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current opioid drugs face high abuse liability, leading to under-treatment of pain and significant social and financial costs, with existing formulations being easily defeated by abusers, and there is a need for drugs that provide safe pain relief while preventing overdose and non-oral abuse.
Innovation Solution
Development of unimolecular polysubunit opioid compositions that include GI enzyme-labile opioid releasing subunits covalently linked to non-opioid releasing GI enzyme subunits or inhibitors, designed to release therapeutic opioid levels at prescribed doses and saturate or inhibit enzyme release at overdose or abuse, using enzyme saturation mechanisms.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If opioid agonists are used for pain management, then analgesic efficacy is improved, but abuse liability and overdose risk increase
Solution Approach 1:
The opioid molecule is divided into multiple subunits (e.g., two or more opioid-containing subunits linked together). These segmented subunits must be taken together to achieve therapeutic effect, but cannot be effectively abused through common methods like crushing or dissolving, as the segmented structure prevents release of sufficient opioid to produce euphoria or overdose
Solution Approach 2:
The patent creates composite opioid structures by covalently linking multiple opioid subunits together with linker moieties. This composite structure maintains therapeutic efficacy when intact is administered, but resists abuse attempts because the composite cannot be easily broken down to release free opioid in abusive dosing scenarios
2Reliability
If higher doses of opioids are administered to overcome tolerance or achieve stronger effect, then analgesic effect may be improved, but overdose risk increases proportionally
Solution Approach 1:
The segmented opioid structure is designed so that even if a patient takes an excessive number of units, the segmented nature and linker chemistry prevent proportional release of active opioid. The system built-in a mechanism where excessive intake does not lead to proportional increase in harmful effects, as the linkers prevent complete dissociation and release of free opioid even under abusive dosing conditions
3Object-affected harmful factors
If opioid formulations are made more resistant to abuse, then abuse liability is reduced, but ease of manufacture and formulation complexity increase
Solution Approach 1:
Multiple opioid subunits are merged into a single covalently-linked molecular structure. This merging creates an integrated molecule that functions as a unified therapeutic agent while inherently resisting abuse. The combined structure eliminates the need for complex physical formulation barriers (like crush-resistant tablets or gelatin capsules) because the molecular structure itself provides the abuse resistance
Solution Approach 2:
Linker moieties serve as intermediary structures connecting opioid subunits. These linkers are designed with specific chemical properties (stability, cleavage characteristics) that mediate between the need for therapeutic release and abuse resistance. The linker acts as a controlled interface that allows legitimate medical use while preventing abuse, without requiring additional formulation complexity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Provides effective pain relief while preventing overdose and abuse by ensuring non-proportional opioid release with excessive doses and minimizing systemic exposure, thus deterring non-oral abuse and protecting against toxic effects.
Implementation Method 1
comprising at least one GI enzyme-labile opioid releasing subunit capable of releasing an opioid agonist upon the action of a GI enzyme
Implementation Method 2
designed to release therapeutic opioid levels at prescribed doses and saturate or inhibit enzyme release at overdose or abuse
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The invention provides compositions and methods for the treatment or prevention of pain. The invention provides constructs whereby hydrolysis of the construct by a specified gastrointestinal enzyme directly, or indirectly, releases an opioid when taken orally as prescribed. The gastrointestinal enzyme mediated release of opioid from constructs of the invention is designed to be attenuated in vivo via a saturation or inhibition mechanism when overdoses are ingested. The invention further provides constructs that are highly resistant to oral overdose, chemical tampering, and abuse via non-oral routes of administration.